Back
NewAmsterdam Pharma Co. NV 10K Form
Buy
51
NAMS
NewAmsterdam Pharma Co. NV
Last Price:
$35.47
Seasonality Move:
-4.57%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive NAMS News And Ratings
See the #1 stock for the next 7 days that we like better than NAMS
NAMS Financial Statistics
Sales & Book Value
| Annual Sales: | $22.5M |
|---|---|
| Cash Flow: | $-41M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $5.97 |
| Price / Book: | 5.77 |
Profitability
| EPS (TTM): | -1.74690 |
|---|---|
| Net Income (TTM): | $-203.8M |
| Gross Margin: | $22.3M |
| Return on Equity: | -27.36% |
| Return on Assets: | -25.14% |
NewAmsterdam Pharma Co. NV Earnings Forecast
Key NewAmsterdam Pharma Co. NV Financial Ratios
-
The Gross Profit Margin over the past 6 years for NAMS is 99.02%.
-
The Selling, General & Administrative Expenses for NAMS have been equal to 472.62% of Gross Profit Margin.
-
The Research & Development expenses have been 630.28% of Revenue.
-
The Net Earning history of NAMS is -905.74% of Total Revenues.
-
Per Share Earnings over the last 6 years have been positive in 2 years.
NewAmsterdam Pharma Co. NV Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | NAMS |
| Website: | newamsterdampharma.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 7.88 |
| Quick Ratio: | 7.43 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
NAMS Technical Analysis vs Fundamental Analysis
Buy
51
NewAmsterdam Pharma Co. NV (NAMS)
is a Buy
Is NewAmsterdam Pharma Co. NV a Buy or a Sell?
-
NewAmsterdam Pharma Co. NV stock is rated a BuyThe current NewAmsterdam Pharma Co. NV [NAMS] share price is $34.28. The Score for NAMS is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.